.png)
.png)
.png)
2026-03-17
The 23rd China International Laboratory Medicine and Blood Transfusion Instrumentation and Reagent Expo, as well as the 6th China International IVD Upstream Raw Materials and Supply Chain Expo, will be grandly held at the Xiamen International Expo Center from March 21st to 23rd, 2026.
At this CACLP exhibition, United Medical will showcase its products such as HPV E6/67 mRNA genotyping assay (new product launch), fluorescence scanning imaging analysis system, flow cytometry detection products, and molecular diagnostic platform (respiratory quad test). We sincerely invite all testing experts and industry colleagues to visit our booth number 2-0705 (located on the right side upon entering through Gate 3 of Hall 2) for visits, guidance, and exchanges. Let's explore new discoveries in testing and discuss new developments in the industry.
As a second-generation detection technology, HPV E6/E7 mRNA detection has been unanimously recognized by experts, with two consensus statements recommending its technical application in 2025. This technology can identify HPV infections that pose a genuine risk of carcinogenesis, detecting and typing 15 high-risk human papillomavirus (HPV) E6/E7 mRNA types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68) present in human cervical exfoliated cell samples. It serves as a risk assessment tool for cervical cancer and precancerous lesions.
United Medical utilizes the latest generation of PCR melting curve technology, eliminating the need for specialized testing equipment and achieving higher sensitivity. It is currently the product with the most certified mRNA detection and typing types both domestically and internationally, adding the common type 53 in the Chinese population for a more comprehensive detection. In combination with HPV DNA testing, mRNA detection effectively distinguishes between transient and persistent infections, provides accurate mRNA typing, guides risk stratification management for cervical cancer, and can directly reflect the expression of HR-HPV E6/E7 oncogenic genes. It can be used as a risk assessment tool for cervical cancer and precancerous lesions.
The Joint Medical Fluorescence Scanning Imaging Analysis System is an automatic morphological analysis system based on multiple fluorescent markers. It allows for flexible selection of various models, including the Gis1000 series, Gis2000 series, and Gis3000 series, and has obtained multiple authoritative certifications such as utility model patents and computer software copyrights. It covers four types of vaginal inflammation: AV, BV, VVC, and TV, and can quickly, accurately, and comprehensively assess various indicators of patients.
Among them, Gis-3100, as a star product, has been used in various top-tier benchmark hospitals and has gained widespread clinical recognition for its excellent performance indicators.
The quadruple detection reagent for influenza A, influenza B, COVID-19, and syncytial respiratory viruses, independently developed by United Medical, utilizes rapid PCR detection method. It can complete the rapid detection of four viruses in a single tube within 30 minutes, suitable for early diagnosis of etiology in outpatient and emergency departments, and provides patients with rapid and precise treatment.
The multi-cytokine detection (multiplex microsphere flow cytometry fluorescence method) can be widely applied to various brands of flow cytometers with APC and PE channels. By detecting cytokine levels, it can assess the inflammatory response and immune status of the body, providing important clinical diagnostic and therapeutic evidence for the prognostic intervention of various infections, tumors, and immune diseases.
Sperm DNA testing is one of the important indicators for evaluating sperm quality. Multiple consensuses have provided relevant explanations on flow cytometry detection, which holds significant detection importance for the etiology investigation and treatment prognosis of male infertility.
CD161 tuberculosis immunoassay is an exclusive product for tuberculosis screening. It utilizes blood samples to conduct a preliminary assessment of tuberculosis risk, with results available in 1 hour. It is fast and efficient, meeting the needs of general hospitals for tuberculosis screening and specialized hospitals for auxiliary detection of tuberculosis diseases.
